First Hawaiian Bank Has $772,000 Holdings in Hologic, Inc. $HOLX

Key Points

• First Hawaiian Bank reduced its stake in Hologic, Inc. by 26.6% in the first quarter, holding a total of 12,506 shares valued at $772,000 after selling 4,522 shares.
• A number of hedge funds have increased their stakes in Hologic, with Victory Capital Management raising its position by 34.4%, now owning 6.6 million shares worth over $408 million.
• Hologic reported better-than-expected earnings of $1.08 per share for the last quarter, exceeding analysts' estimates, and has set its Q4 2025 guidance between $1.090 and $1.120 EPS.

First Hawaiian Bank cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 26.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,506 shares of the medical equipment provider's stock after selling 4,522 shares during the period. First Hawaiian Bank's holdings in Hologic were worth $772,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Victory Capital Management Inc. lifted its position in Hologic by 34.4% during the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after acquiring an additional 1,692,177 shares during the last quarter. Invesco Ltd. lifted its position in Hologic by 18.8% during the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock worth $298,655,000 after acquiring an additional 764,573 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Hologic by 1.6% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider's stock valued at $276,303,000 after buying an additional 69,878 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of Hologic by 0.8% in the first quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider's stock valued at $216,973,000 after buying an additional 29,133 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Hologic by 8.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider's stock valued at $175,331,000 after buying an additional 213,366 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on HOLX. Argus upgraded shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 price target for the company in a research report on Monday, August 18th. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Mizuho set a $75.00 price target on shares of Hologic in a research report on Thursday, July 31st. Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and lifted their price objective for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Finally, UBS Group boosted their price objective on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $78.00.

Hologic Stock Performance

NASDAQ HOLX opened at $64.45 on Monday. The firm's fifty day moving average price is $66.43 and its two-hundred day moving average price is $62.64. The stock has a market cap of $14.33 billion, a PE ratio of 26.74, a PEG ratio of 2.34 and a beta of 0.57. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company's revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.